A Review of Antithrombotic Therapy and the Rationale and Design of the Randomized Edoxaban in Patients With Peripheral Artery Disease (ePAD) Trial Adding Edoxaban or Clopidogrel to Aspirin After Femoropopliteal Endovascular Intervention
Marco J.D. Tangelder(UniQure (Netherlands)), Frans L. Moll(Metallco (Norway)), Anil Duggal(Daiichi Sankyo (United States)), Michele Mercuri(Inserm), Gary M. Ansel(Clinical Insights), Iris Baumgärtner(Hirslanden Klinik Beau-Site), George L. Adams(Rex Hospital), Michael Grosso(Daiichi Sankyo (United States)), Minggao Shi(Daiichi Sankyo (United States)), Erich Minar(Medical University of Vienna), Chuke Nwachuku(National Heart Lung and Blood Institute), Michael R. Jaff(Boston Scientific (United States))
Cited by 19
Related Papers
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk Patients
|New England Journal of Medicine|2004|2.9k
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
|Blood Advances|2020|1.4k
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k
Editor's Choice – Management of Descending Thoracic Aorta Diseases
|European Journal of Vascular and Endovascular Surgery|2017|1.2k